CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...

Some biotechnology companies, such as CRISPR Therapeutics (NASDAQ: CRSP), hope to use gene editing technology to treat, or even cure, diseases that existing drugs cannot. Where to invest $1,000 ...

CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

Some biotechnology companies, such as CRISPR Therapeutics (NASDAQ: CRSP), hope to use gene editing technology to treat, or even cure, diseases that existing drugs cannot. CRISPR Therapeutics ...

Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders. Under the agreement ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.

CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co-develop an siRNA drug targeting blood clotting disorders. This marks a ...